Short description:
Cellular Engineering Tools (CRISPR)
Drug notes:
CB-011 Clin1 multiple myeloma; CB-012 Clin0 AML; CB-020 RD solid tumors; 2 undisclosed programs RD undisclosed
Long description:
Caribou Biosciences is developing CRISPR technologies to create allogeneic cell therapies for oncology. Caribou has built CRISPR hybrid RNA-DNA (chRDNA), their proprietary technology that enables highly efficient, highly specific genome editing. chRDNA is then used to develop sophisticated genome-edited cell therapies. For example, Caribou is using chRDNA to create next-generation allogeneic CAR-T and CAR-NK cell therapies to enhance the longevity and persistence of the cells. Scientific advances have been published in high-impact journals. Caribou has one ongoing Phase I clinical trial to evaluate CB-010 in adults with relapsed B cell non-Hodgkin lymphoma.
Jobs:
Corporate Communications Intern - Summer 2024 Berkeley, CA|3 days ago
Research Associate 1/2 (cell biology) Berkeley, CA|9 days ago
Regulatory Operations Manager Berkeley, CA|16 days ago
Animal Care Technician Berkeley, CA|22 days ago
Sample Management Specialist Berkeley, CA|24 days ago
Senior Scientist 1, Analytical Development Berkeley, CA|28 days ago
Senior Director of Human Resources Berkeley, CA|38 days ago
Scientist, Analytical Development Berkeley, CA|39 days ago
Scientist, Platform Discovery Berkeley, CA|43 days ago
Vice President of Quality Berkeley, CA|45 days ago
Senior Counsel, Transactions Berkeley, CA|51 days ago
Senior Manager / Associate Director of Clinical Da... Berkeley, CA|57 days ago